AORT — Stock Film
STOCK FILMSCENE 1/11AORT · $28.08
Stock Expert AI presents
AORT
Artivion, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Artivion, Inc. A quick introduction.

On the stock market since 1993, it operates in the world of health and science. It has 1,600 employees. Now — the numbers.

on the stock market since 1993
1,600 employees
$1.7B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $2 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 2%

This is an established company with proven profits.

THE SALES TREND
Sales are growing, year after year.

Average growth of 10% a year over the last 4 years. Red columns mark years that ended in a loss.

$298.8M
2021
$313.8M
2022
$354M
2023
$388.5M
2024
$441.3M
2025
Cash on hand:
$0
Total debt:
$0
The debt outweighs the cash.

The gap is $227.1M. In times of high interest rates, a gap like that can squeeze a company.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
75
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
13
very weak

Clearly below the class average.

VALUATION
61
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
61
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
36
weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
WEAK SPOTS
The stock has lost its spark0/10
THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 41% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
Sales keep climbing

Over the last 3 years, sales grew about 12% a year on average.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $42.5051% above today’s price.

1
THE RISKS · 1/3
A rich price tag

The company’s market value is 178 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 13/100.

3
THE RISKS · 3/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 36/100. For a turnaround signal, the stock first needs to close the gap with the market.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, AORT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: AORT is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 22, 2026 · stockexpertai.com · Stock Film